Latest Global Growth News

BKI Investment Company reported a solid half-year performance with a 7% rise in operating results and a 1% increase in fully franked dividends, driven by a strategic portfolio rotation favoring resource stocks aligned with global growth themes.

Talius Group reported a positive operating cash flow for the December quarter, alongside a 3% rise in subscriptions and a $4 million capital placement. The company also announced a CEO succession and expanded its international footprint with new pilot programs.

Pureprofile has reported record first-half FY26 results, driven by strong international expansion and AI-powered platform growth, prompting an upgrade to its full-year revenue guidance.

Temas Resources has appointed Nic Matich as a Non-Executive Director to spearhead Australian investor relations and business development, while CFO David Robinson transitions to a full-time executive role to sharpen financial oversight amid the company’s growth and commercialisation push.

Savana Asset Management’s SVNP ETF delivered a standout 12.9% net return in 2025, outperforming major US equity ETFs despite a volatile year marked by geopolitical tensions and AI-driven market narratives.

Servcorp Limited has upgraded its FY2026 profit and cash flow guidance, reflecting robust operational momentum and improved revenue efficiency across its global serviced office portfolio.

Genetic Signatures reported a $3.3 million quarterly revenue with growing international sales and a robust cash position, while preparing for a leadership change.

Neuren Pharmaceuticals’ partner Acadia projects DAYBUE sales to reach around US$700 million by 2028, driven by US market expansion and international approvals. The launch of a new formulation and ongoing clinical trials in Japan underpin this optimistic outlook.

RocketBoots Limited has slightly increased its recent capital raising, issuing an additional 100,000 shares to raise a total of A$7.025 million, reinforcing its push into international markets.

CurveBeam AI has received official Chinese regulatory approval for a strategic $10 million investment from WEGO Orthopaedics, marking a major step in its expansion into Greater China. The initial $4 million tranche at a premium share price is expected imminently, underpinning a decade-long commercialisation deal.

WAM Active Limited has reported its strongest investment performance since inception, with a 41.4% return over 12 months and increased fully franked dividends, signalling confidence in its dynamic portfolio strategy heading into 2026.

Memphasys has secured CE Mark approval for its Felix™ sperm selection system, enabling full commercial rollout across Europe and activating multi-year contracts worth over A$1.3 million. This milestone signals the company’s transition into a revenue-scaling phase with global growth ambitions.